Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medrx CoTSE:4586 +3.64%57 Current Ratio is 23.62 as of Dec. 2025, which is 42% above its 10-year median of 16.62. GuruFocus rates TSE:4586 with a GF Score™ of 57/100 and a GF Value™ of 円70.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,000 Drug Manufacturers companies, Medrx Co ranks better than 95.5% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Medrx Co's current ratio for the quarter that ended in Dec. 2025 was 23.62.
Medrx Co has a current ratio of 23.62. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Medrx Co's Current Ratio or its related term are showing as below:
TSE:4586'
s Current Ratio Range Over the Past 10 Years
Min: 6.87 Med: 16.62 Max: 26.51
Current: 12.95
During the past 13 years, Medrx Co's highest Current Ratio was 26.51. The lowest was 6.87. And the median was 16.62.
TSE:4586's Current Ratio is ranked better than 95.5% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs TSE:4586: 12.95
Medrx Co (TSE:4586) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Medrx Co Current Ratio Related Terms
Medrx Co Current Ratio Historical Data
* Premium members only.
The historical data trend for Medrx Co's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medrx Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medrx Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medrx Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Medrx Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medrx Co (TSE:4586) has a Current Ratio of 23.62 as of Dec. 2025. This is 42% above median its historical median of 16.62. Over the past decade, Medrx Co's Current Ratio has ranged from 6.87 to 26.51. According to the industry distribution chart, Medrx Co ranks #45 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 4.5%.
Is Medrx Co's Current Ratio too high?
Medrx Co's current Current Ratio of 23.62 is 42% above median its 10-year median of 16.62. Over the past 10 years, this metric has ranged from a low of 6.87 to a high of 26.51. The Drug Manufacturers industry median Current Ratio is 2.00. Medrx Co's value of 23.62 is 1081% above this industry median. Based on the distribution chart, Medrx Co ranks #45 out of 1000 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medrx Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medrx Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medrx Co ranks #45 out of 1000 companies for Current Ratio. This places Medrx Co in the top 5% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Medrx Co's value of 23.62 is 1081% above this benchmark. Historically, Medrx Co's own Current Ratio has ranged from 6.87 to 26.51 over the past decade. While the company's 10-year median is 16.62 vs. the industry median of 2.00, Medrx Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medrx Co's current Current Ratio of 23.62 is 1081% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medrx Co's current Current Ratio is 23.62, which is 42% above median its own 10-year median of 16.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medrx Co stock overvalued right now?
Based on GuruFocus' analysis, Medrx Co (TSE:4586) is currently considered Modestly Undervalued. The stock's GF Value™ is 円70.55, compared to a current price of 円57.00 — trading 19.2% below its estimated fair value. The current Current Ratio is 23.62, which is 42% above median its 10-year median of 16.62 and 1081% above the Drug Manufacturers industry median of 2.00. Medrx Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Medrx Co (TSE:4586), the current Current Ratio is 23.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medrx Co (TSE:4586) Overvalued in 2026?
Based on GuruFocus' analysis, Medrx Co stock appears to be undervalued.
The current stock price of 円57.00 is trading 19.2% below its estimated GF Value™ of 円70.55.
GuruFocus considers Medrx Co to be Modestly Undervalued.
Key valuation signals for TSE:4586:
Current Ratio: 23.62 (42% above median its 10-year median of 16.62)
GF Value™: 円70.55 vs. price of 円57.00 (19.2% below fair value)
Industry Position: 1081% above the Drug Manufacturers median (#45 of 1000)
No single metric tells the full story. See the TSE:4586 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medrx Co Ltd is a pharmaceutical drug development company founded in January, 2002. The Company engaged in the research and development of pharmaceutical products utilizing the pharmaceutical formulation technology based on ionic liquid transdermal system. The Company develops new pharmaceutical candidates and licenses other companies to produce the pharmaceuticals after clinical trials. Its main products include analgesic patches for anti-inflammatory and pain relief.
57GF Score
Get the complete analysis for TSE:4586
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4586 has been successfully added to your 
